



# HRI 2016 Acute Inpatient Phase 3 Placebo-Controlled Double-Blind Schizophrenia Results: Separation Between Drug and Placebo!

## HRI Enrollment Achievement

- HRI was highest enrolling US site (n=18)
- HRI was 4th highest enrolling site globally

## Study Results

- Study showed ample efficacy separation from placebo, resulting in Sponsor meeting with FDA for final drug approval
- While HRI's data alone could not be analyzed for statistical significance given the low n, study results did indicate significant separation between active drug and placebo and Sponsor attributed much of this success to HRI's data!

## HRI Performance Success

- Sponsor deemed HRI's systemic placebo effect reduction interventions, subject selection, as well as experienced Psychometric Raters and site staff crucial to their clinical trial success
- While Sponsors consistently inform HRI of our significant active drug and placebo separation performance, this sponsor has graciously allowed us to view and share the data (with sponsor and specific trial methods anonymity)
- Sponsor invited one of HRI's Principal Investigators to their Scientific Advisory Board as a result of site's performance/expertise

